Chemistry: molecular biology and microbiology – Vector – per se
Patent
1997-04-14
2000-02-01
Guzo, David
Chemistry: molecular biology and microbiology
Vector, per se
536 235, C12N 1586
Patent
active
060201916
ABSTRACT:
The invention is directed to novel adenoviral vectors which are capable of facilitating persistent expression of a transgene which is delivered by the vector to a cell. The vectors are E1/partial E3 deleted vectors which contain a transgene operably linked to expression control sequences, preferably the CMV promoter. The invention is also directed to compositions comprising the adenoviral vectors of the invention and to methods for providing persistent expression of a transgene to the cells of an individual by administration of the compositions.
REFERENCES:
patent: 5747469 (1998-05-01), Roth et al.
Verma et al., Nature, vol. 389, pp. 239-242, Sep. 18, 1997.
Lee et al., Gene Therapy, vol. 2, pp. 256-262, 1995.
Orkin et al., "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy", Dec. 7, 1995.
Berkner, K.L., Curr. Top. Micro. Immunol. 158:39-66, 1992.
Graham, F.L., J. Gen. Virol. 36:59-72, 1977.
Zhou et al., J. Virol. 70:7030-7038, 1996.
Krougliak et al., Hum. Gene Ther. 6:1575-1586, 1995.
Caravokyri et al., J. Virol. 69:6627-6633, 1995.
Kochanek et al., Proc. Natl. Acad. Sci. USA 93:5731-5736, 1996.
Fisher et al., Virology 217:11-22, 1996.
Wills et al., Hum. Gene Ther. 5:1079-188, 1994.
Vincent et al., Nature Genetics 5:130-134, 1993.
Descamps et al., Hum. Gene Ther. 5:979-985, 1994.
Stratford-Perricaudet et al., Hum. Gene Ther. 1:241-256, 1990.
Mitani et al., Hum. Gene Ther. 5:941-948, 1994.
Haddada et al., Hum. Gene Ther. 4:703-711, 1993.
Jaffe et al., Nature Genetics 1:372-378, 1992.
Ohwada et al., Blood 88:778-784, 1996.
Ohwada et al., Hum. Gene Ther. 7:1567-1576, 1996.
Zabner et al., Nature Genetics 6:75-83, 1994.
Rich et al., Hum. Gene Ther. 4:461-476, 1993.
Zabner et al., Cell 75:207-216, 1993.
Crystal et al., Nature Genetics 8:42-51, 1994.
Zabner et al., J. Clin. Invest. 97:1504-1511, 1996.
Yang et al., J. Virol. 69:2004-2015, 1995.
Yang et al., Proc. Natl. Acad. Sci. USA 91:4407-4411, 1994.
Zsengeller et al., Hum Gene Ther. 6:457-467, 1995.
Worgall et al., Hum. Gene Ther. 8:37-44, 1997.
Kaplan et al., Hum. Gene Ther. 8:45-56, 1997.
Smith, G.L., Trends Microbiol. 2:81-88, 1994.
Crystal, R., Science 270:404-410, 1995.
Fang et al., Hum. Gene Ther. 6:1039-1044, 1995.
Kay et al., Nature Genetics 11:191-197, 1995.
Mack et al., Hum. Gene Ther. 8:99-109, 1997.
Barr et al., Gene Ther. 2:151-155, 1995.
Guo et al., Gene Ther. 3:802-801, 1996.
Tripathy et al., Nature Med. 2:545-550, 1996.
Yang et al., Nature Genetics 7:362-369, 1994.
Lieber et al., J. Virol. 70:8944-8960, 1996.
Gorziglia et al., J. Virol. 70:4173-4178, 1996.
Brody et al., Hum. Gene Ther. 5:821-836, 1994.
Wold et al., Trends Microbiol. 2:437-443, 1994.
Tollefson et al., J. Virol. 70:2296-2306, 1996.
Tollefson et al., Virology 220:152-162, 1996.
Armentano et al., Hum. Gene Ther. 6:1343-1353, 1995.
Armentano et al., J. Virol. 71:2408-2416, 1997.
Hehir et al., J. Virol. 70:8459-8467, 1996.
Ginsberg et al., Proc. Natl. Acad. Sci. USA 88:1651-1655, 1991.
Sparer, T.E. et al., Generation of cytotoxic T lymphocytes, J. Virol. 71:2277-2284, 1997.
Scaria et al., J. Virol, vol. 72, No. 9, pp. 7302-7309, Sep. 1998.
Gregory Richard J.
Scaria Abraham
Wadsworth Samuel C.
Genzyme Corporation
Guzo David
LandOfFree
Adenoviral vectors capable of facilitating increased persistence does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adenoviral vectors capable of facilitating increased persistence, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adenoviral vectors capable of facilitating increased persistence will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-936729